Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.
Highlights:
Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December.
Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion.
Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process.
Completion of usability study for submission for additional OTC clearance for the Pulse.
Strong clinical sales pipeline with momentum towards new Q2 contracts.
Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding.
New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.
Click here for the September Quarterly Appendix 4C
Click here for the full ASX Release
